Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M61,576Revenue (TTM) $M11,416Net Margin (%)34.0Altman Z-Score6.3
Enterprise Value $M63,792EPS (TTM) $17.7Operating Margin %47.6Piotroski F-Score5
P/E(ttm)16.0Beneish M-Score-2.3Pre-tax Margin (%)45.4Higher ROA y-yN
Price/Book5.110-y EBITDA Growth Rate %26.0Quick Ratio2.8Cash flow > EarningsY
Price/Sales5.55-y EBITDA Growth Rate %30.6Current Ratio3.2Lower Leverage y-yY
Price/Free Cash Flow19.3y-y EBITDA Growth Rate %18.3ROA % (ttm)18.6Higher Current Ratio y-yN
Dividend Yield %--PEG0.5ROE % (ttm)36.1Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M218ROIC % (ttm)31.0Gross Margin Increase y-yN

Gurus Latest Trades with BIIB

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BIIBKen Fisher 2016-12-31 Add$273.49 - $324.4
($296.43)
$ 283.01-5%Add 1.16%101,887
BIIBJohn Paulson 2016-09-30 Add0.64%$242.03 - $330.11
($296.18)
$ 283.01-4%Add 150.20%308,000
BIIBJoel Greenblatt 2016-09-30 Reduce-0.36%$242.03 - $330.11
($296.18)
$ 283.01-4%Reduce -33.31%245,468
BIIBFirst Eagle Investment 2016-09-30 Add0.1%$242.03 - $330.11
($296.18)
$ 283.01-4%Add 37.41%457,260
BIIBHOTCHKIS & WILEY 2016-09-30 Add0.1%$242.03 - $330.11
($296.18)
$ 283.01-4%Add 33.67%306,100
BIIBVanguard Health Care Fund 2016-09-30 Reduce-0.1%$242.03 - $330.11
($296.18)
$ 283.01-4%Reduce -4.98%3,759,703
BIIBRon Baron 2016-09-30 Reduce-0.02%$242.03 - $330.11
($296.18)
$ 283.01-4%Reduce -66.48%6,577
BIIBGeorge Soros 2016-09-30 Buy 0.02%$242.03 - $330.11
($296.18)
$ 283.01-4%New holding1,994
BIIBRonald Muhlenkamp 2016-09-30 Reduce-0.02%$242.03 - $330.11
($296.18)
$ 283.01-4%Reduce -0.95%23,478
BIIBMario Gabelli 2016-09-30 Reduce-0.01%$242.03 - $330.11
($296.18)
$ 283.01-4%Reduce -60.45%1,897
BIIBRichard Pzena 2016-09-30 Buy $242.03 - $330.11
($296.18)
$ 283.01-4%New holding642
BIIBKen Fisher 2016-09-30 Reduce$242.03 - $330.11
($296.18)
$ 283.01-4%Reduce -1.18%100,718
BIIBHOTCHKIS & WILEY 2016-06-30 Buy 0.24%$224.6 - $290.23
($263.49)
$ 283.017%New holding229,000
BIIBJoel Greenblatt 2016-06-30 Add0.2%$224.6 - $290.23
($263.49)
$ 283.017%Add 23.24%368,095
BIIBVanguard Health Care Fund 2016-06-30 Add0.08%$224.6 - $290.23
($263.49)
$ 283.017%Add 3.85%3,956,663
BIIBFirst Eagle Investment 2016-06-30 Add0.07%$224.6 - $290.23
($263.49)
$ 283.017%Add 48.17%332,760
BIIBRonald Muhlenkamp 2016-06-30 Reduce-0.02%$224.6 - $290.23
($263.49)
$ 283.017%Reduce -0.63%23,703
BIIBDavid Dreman 2016-06-30 Buy 0.02%$224.6 - $290.23
($263.49)
$ 283.017%New holding150
BIIBJohn Paulson 2016-06-30 Add0.01%$224.6 - $290.23
($263.49)
$ 283.017%Add 3.97%123,100
BIIBKen Fisher 2016-06-30 Add0.01%$224.6 - $290.23
($263.49)
$ 283.017%Add 12.74%101,919
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BIIB is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BIIB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PANGIA ROBERT WDirector 2017-01-09Sell5,450$295.39-3.6view
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff 2016-12-01Sell48$296.53-3.97view
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff 2016-10-04Sell262$311.94-8.72view
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp Aff 2016-10-03Sell380$313-9.03view
DORSA CAROLINEDirector 2016-09-22Sell27,570$314-9.32view
SCANGOS GEORGE ACEO 2016-07-21Sell157$2801.7view
Koppel AdamEVP, Strategy and Bus. Dev. 2016-06-06Sell555$290-1.81view
SCANGOS GEORGE ACEO 2016-06-03Sell842$290-1.81view
SCANGOS GEORGE ACEO 2016-06-01Sell3,855$289.74-1.72view
SCANGOS GEORGE ACEO 2016-05-25Sell157$2801.7view

Press Releases about BIIB :

Quarterly/Annual Reports about BIIB:

News about BIIB:

Articles On GuruFocus.com
Steven Romick Spots Next Area of Interest, Health Care Jan 13 2017 
John Paulson Continues to Buy These 8 Stocks Dec 23 2016 
Health Care Companies Showing Good Defensive Potential Dec 22 2016 
John Paulson's Largest 3rd Quarter Trades Dec 01 2016 
Gurus Invest in Undervalued Biotech Stocks Nov 25 2016 
Paul Tudor Jones Exits EMC, Boosts Facebook, PepsiCo, Biogen Nov 23 2016 
Jeff Auxier Expands Holdings in Chemical and Biotech Companies Nov 21 2016 
Vanguard Health Care Fund Sells Amgen, Baxter Nov 02 2016 
First Eagle Fund of America 3rd Quarter Commentary Oct 28 2016 
Eaton Vance Worldwide Health Sciences Fund 3rd Quarter Commentary Oct 26 2016 

More From Other Websites
Biogen to pay $1.25B settlement in multiple sclerosis drug case Jan 17 2017
Forward Pharma stock skyrockets 53% on $1.25 bln cash licensing agreement with Biogen Jan 17 2017
BIOGEN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Jan 17 2017
Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement Jan 17 2017
New and Returning Bio-Tech Stock Picks for 2017 Jan 17 2017
Biogen Says Spinraza Drug Did Well In Phase 3 Trial Jan 16 2017
Biogen (BIIB) Presents Positive Phase III Data on Spinraza Jan 16 2017
7:30 am Biogen presents Phase 3 ENDEAR study data of SPINRAZA; met the pre-specified primary... Jan 16 2017
Biogen's latest drug may be costly, but new data suggests it saves lives Jan 13 2017
Biogen Spinoff Bioverativ In Good Shape for Launch Jan 13 2017
Ionis Has High Hopes for Heart Drug Volanesorsen Jan 13 2017
Bioverativ Makes Splash in Trading Debut, Gaining 18% on Day One Jan 13 2017
New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation... Jan 13 2017
New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation... Jan 13 2017
Biotech Short Sellers Run for Cover Jan 12 2017
Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock Jan 12 2017
Choppy Day As Trump Targets Pharma, Lockheed; Netflix, Amazon Up Jan 11 2017
Trump's Comments Slam Drug Stocks Jan 11 2017
Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : January 11, 2017 Jan 11 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)